


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	FISHMAN10A
		Filing Date	October 21, 2003
		First Named Inventor	Pnina FISHMAN
		Group Art Unit	
		Examiner Name	
Sheet 1	of 1	Attorney Docket Number	FISHMAN10A




OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
HS	AA	BONVINI et al "Nuclear $\beta$ -catenin displays GSK-3 $\beta$ - and APC-independent proteasome sensitivity in melanoma cells," <u>Biochimica et Biophysica Acta</u> 1495: 308-318 (2000)	
	AB	FANG et al "Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A," <u>PNAS</u> 97 (22): 11960-11965 (October 24, 2000)	
	AC	FERKEY et al "GSK-3: New Thoughts on an Old Enzyme," <u>Developmental Biology</u> 225: 471-479 (2000)	
	AD	FISHMAN et al "Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells," <u>Oncogene</u> 21: 4060-4064 (2002)	
	AE	OLAH et al "The role of receptor structure in determining adenosine receptor activity," <u>Pharmacology &amp; Therapeutics</u> 85: 55-75 (2000)	
HS	AF	POULSEN et al "Adenosine Receptors: New Opportunities for Future Drugs," <u>Bioorganic &amp; Medicinal Chemistry</u> 6: 619-641 (1998)	

Examiner Signature	/Hong Sang/ (06/09/2006)	Date Considered	06/09/2006
-----------------------	--------------------------	--------------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**BEST AVAILABLE COPY**



PTO/SB/08a (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

### Complete if Known

Application Number	10/689,550
Filing Date	October 21, 2003
First Named Inventor	Prina FISHMAN
Group Art Unit	
Examiner Name	
Attorney Docket Number	FISHMAN10A

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
HS	AG	US 6,376,521	04-03-2002	Li, et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
HS	AH	WO 01/19360 A2	03-22-01	Can-Fite Technologies Ltd.		
HS	AI	WO 97/38125 A1	10-16-97	Thomas Jefferson U		

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
HS	AJ	FISHMAN, et al, "A3 Adenosine Receptor as a Target for Cancer Therapy," <u>Anti-Cancer Drugs</u> 13(5):437-443 (2002)	
HS	AK	FISHMAN, et al, "Pharmacology and Therapeutic Applications of A <sup>3</sup> Receptor Subtype," <u>Current Topics in Medicinal Chemistry</u> 3(4):463-469 (2003)	
HS	AL	MADl, et al, "High Expression of A <sup>3</sup> ARS in Melanoma and Colon Carcinoma Cell Lines: A Target for Tumor Cell Growth Inhibition," <u>Drug Development Research</u> 56(4):560 (2002) (XP009024523; Seventh International Symposium on Adenosine and Adenine Nucleotides; Queensland, Australia; May, 2002)	

Examiner Signature	/Hong Sang/ (06/09/2006)	Date Considered	06/09/2006
-----------------------	--------------------------	--------------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**BEST AVAILABLE COPY**